← Back to Clinical Trials
Recruiting NCT07585045

NCT07585045 Effectiveness of Oral Magnesium Supplementation in Fibromyalgia Patients Not Responding to Standard Treatment

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07585045
Status Recruiting
Phase
Sponsor Shaikh Zayed Hospital, Lahore
Condition Fibromyalgia
Study Type INTERVENTIONAL
Enrollment 86 participants
Start Date 2026-04-16
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Magnesium glycinateVitamins

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 86 participants in total. It began in 2026-04-16 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Fibromyalgia is a complex widespread pain disorder. OBJECTIVES To evaluate the effectiveness of oral magnesium supplementation in reducing symptom severity among fibromyalgia patients who have not responded to standard treatment, using validated scoring systems such as the Fibromyalgia Impact Questionnaire Revised (FIQR).

Eligibility Criteria

Inclusion Criteria: 1. Patients diagnosed with FM according to the American College of Rheumatology (ACR) 2016 criteria 2. Age: 18-65 years. 3. Not responding to conventional treatment (e.g., amitriptyline, duloxetine, pregabalin) for at least 8 weeks 4. Patients giving informed consent for enrollment in the study. Exclusion Criteria: * 1- Patients with renal impairment 2- Pregnant or lactating women 3- Already on magnesium or other mineral supplements 4- Known cases of inflammatory arthritis or other chronic pain syndromes

Contact & Investigator

Central Contact

Masooma Hashmat, FCPS

✉ masoomahashmat@gmail.com

📞 +923353053304

Principal Investigator

Masooma Hashmat, FCPS

PRINCIPAL INVESTIGATOR

Shaikh Zayed Hospital, Lahore

Frequently Asked Questions

Who can join the NCT07585045 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Fibromyalgia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07585045 currently recruiting?

Yes, NCT07585045 is actively recruiting participants. Contact the research team at masoomahashmat@gmail.com for enrollment information.

Where is the NCT07585045 trial being conducted?

This trial is being conducted at Lahore, Pakistan.

Who is sponsoring the NCT07585045 clinical trial?

NCT07585045 is sponsored by Shaikh Zayed Hospital, Lahore. The principal investigator is Masooma Hashmat, FCPS at Shaikh Zayed Hospital, Lahore. The trial plans to enroll 86 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology